Showing results (11-20 of 37) with videos related to
Sort By:
Pageof 4
Vaccine|September 7, 2023
Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the USHong-Van Tieu, Shelly Karuna, Yunda Huang, et al.Medrxiv : the Preprint Server for Health Sciences|September 21, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine EvaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.Research Square|September 8, 2021
Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine EvaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.Human Vaccines & Immunotherapeutics|July 2, 2021
Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participantsYunda Huang, Lily Zhang, Amanda Eaton, et al.Scientific Reports|December 15, 2021
Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluationYunda Huang, Oleg Borisov, Jia Jin Kee, et al.Journal of Global Health|June 23, 2023
Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global regionShelly Karuna, Jorge A Gallardo-Cartagena, Deborah Theodore, et al.PLOS Global Public Health|September 11, 2025
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort studyNonhlanhla N Mkhize, Shuying Sue Li, Jiani Hu, et al.Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.The Lancet. HIV|October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trialGiuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.Plos Computational Biology|April 2, 2019
Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence featuresCraig A Magaret, David C Benkeser, Brian D Williamson, et al.Pageof 4